Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix Proactive financial news
Cardiothoracic involvement by obstetric and gynecologic pathologic conditions creates a broad spectrum of clinical and radiologic manifestations, ranging from mild to critical. The authors describe the unique and often unrecognized …
Endometriosis is a prevalent gynecological condition affecting up to 25-40% of women with infertility. Endoferin, a protein complex derived from the bovine ovarian follicles, has demonstrated high efficacy in clinical …
Decidual changes in deep pelvic endometriosis (DPE) are extremely rare. During pregnancy, endometriotic activity and symptoms diminish due to hormonal changes, whereas the endometrial lining undergoes decidualization in response to …
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint tipranks.com
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer Karyopharm